Post

New research · Nephrology
British journal of haematology · 23h
GuidelineBritish journal of haematology · 2026

Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline.

Mamta Garg, Satarupa Choudhuri, Christopher Parrish … Ashutosh Wechalekar
Read paper
NephrologyGuideline

Early diagnosis of AL amyloidosis is linked to approximately 80% 5-year survival.

Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline.

Mamta Garg et al. · British journal of haematology · 2026
Background

AL amyloidosis is caused by a plasma cell clone that produces abnormal light chains that misfold and deposit as amyloid fibrils in tissues and thus affect organ function.

Purpose

The aim of this guideline is to facilitate recognition and raise suspicion of amyloidosis.

Methods

With early-stage disease can expect approximately 80% survival at 5 years with contemporary treatment, compared to less than 30% for those with advanced disease.

Results
how many people with early AL amyloidosis are expected to live for 5 years
More results

The survival of patients with systemic amyloid light-chain (AL) amyloidosis largely depends on the extent of end-organ damage.

“
Conclusion

It is important to recognise that amyloidosis can present in any clinic, including general medicine/care of the elderly and general practice.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
hazard ratio 4.00
high genetic risk and severe CKM syndrome meant a much higher risk of knee arthritis
Cohort Study
11.1%
hospitalizations for heart inflammation in dialysis patients that included severe heart issues
Cohort Study
HR 4.00
Severe kidney scarring linked to about 4-fold higher rate of graft failure
Guideline
almost 30%
people with Von-Hippel Lindau syndrome are affected by kidney cancer
Cohort Study
14.0%
About 1 in 7 survivors without prior risk factors had persistent kidney damage
Guideline
“This consensus aims to clarify for which patients renal denervation may be a viable therapeutic option, identify the main clinical and procedural considerations for its implementation, and promote its optimal and safe use through appropriate patient selection and multidisciplinary evaluation.”
Cohort Study
-41.5 mg/dL
GLP-1 RAs were associated with lower total cholesterol
Cohort Study
27.89
lupus nephritis patients have a cardiovascular death risk this many times higher than the general population